tbuckley/cabot-search huggingface dataset:
SEQUENTIAL INHIBITION OF RENIN-ANGIOTENSIN SYSTEM IN HEART FAILURE IS ASSOCIATED WITH ENHANCED NET BENEFIT AT A COST OF INCREASED ADVERSE EVENTS: A SYSTEMATIC META-ANALYSIS
Authors: Saurabh Aggarwal, Rohit Loomba, Nawfal Al-Khafaji, Gaurav Aggarwal, Venkata Alla, Rohit Arora
Journal: Journal of the American College of Cardiology (2017)
The International Core Literature Consensus (ICLC) : A tool for Resident training
Authors: N. Cook, C. A. Parkinson, R. Jagsi, S. Patel, L. Hughes-Davies
Journal: Journal of Clinical Oncology (2006)

10545 Background: Teaching residents is a responsibility of almost all oncology attendings. Although much effort is put into direct teaching, there is often little attention paid to the structuring of reading. Many professional societies (including ASCO) publish detailed curriculum documents to guide study. However it is not clear how useful these are. They tend to be over-inclusive and offer no advice about what to read. We propose an alternative approach: The International Core Literature Consensus (ICLC). Here we have tested this approach using breast cancer as an example. Methods: We identified 40 highly cited breast oncology investigators and invited them to join an Expert Panel. The panel was asked to select the 100 most important papers in breast cancer. We define the ‘Core Literature‘ as those papers which a resident should have read by the end of their first rotation through a breast cancer service. We also surveyed residents to find out how useful they have found existing curriculum documents and what sort of curriculum they might find helpful. Results: Using the Expert Panel, we were rapidly able to define a core list of the 100 most important papers in breast cancer medicine. There was a surprising level of agreement between Experts (&gt;90% concordance). Most of the disagreement was over whether some historically important but now out of date papers (such as the original Bonadonna description of CMF) should be included. Initial results from our residents survey suggest that although many residents (60%) are aware of the ASCO curriculum, few find it helpful (27%). Very few trainees have been given a detailed reading guide (9%) although all (100%) felt that it was very important to have such recommendations to guide their reading. Conclusions: Residents find the ASCO curriculum document unhelpful for structuring their reading and want better recommendations. We used an Expert Panel to define an International Core Literature Consensus, an alternative form of curriculum which our survey shows is closer to what residents find helpful. Such a core consensus could easily be constructed for every tumour site and updated every year. No significant financial relationships to disclose.
Single institution experience of chemoradiation with gemcitabine versus capecitabine in borderline resectable and locally advanced pancreatic cancer.
Authors: Adam S. Kotowski, Naveen Yarlagadda, Kilian Salerno May, Graham Walter Warren, Boris W. Kuvshinoff, Neal W. Wilkinson, Wei Tan, Renuka V. Iyer, Wen Wee Ma
Journal: Journal of Clinical Oncology (2012)

e14659 Background: To retrospectively evaluate the outcome of borderline resectable (BR) and locally advanced unresectable (LA) pancreatic cancer patients treated with concurrent chemoradiotherapy (CRT) with gemcitabine (G) or capecitabine (C). Methods: Retrospective chart review of patients treated between August 2005 and September 2011 generated 30 BR and 40 LA pts. Cases were analyzed for patient and treatment characteristics including age, gender, weight loss, ECOG PS, albumin, stage, grade, location, pathology, laboratory values, chemotherapy (CT) regimens, radiotherapy dose and technique, and toxicity using CTCAE v.4.0. Endpoints evaluated were surgical resection rate, progression free survival (PFS), and median overall survival (mOS). Results: Patient characteristics were comparable between CRT/G and CRT/C in both BR and LA patients. Gemcitabine iv 300mg/m 2 weekly or capecitabine po 825mg/m 2 BID were used during CRT. Among BR patients who received CRT (n=21), 17 (56.6%) received CRT/G, 4 (13.3%) CRT/C, and others received CT alone. For BR, surgical resection was performed in 52.9% of CRT/G patients. The PFS were 17.4 months (m) and 4.8m (p=0.009), and mOS were 21.9m and 5.7m (p=0.004) for CRT/G and CRT/C respectively. For LA patients who received CRT (n=25), 18% of CRT/G underwent surgical resection and none of CRT/C did. The PFS 8.4m and 10.4m (p=0.63) and mOS were 14.9m and 11.5m (p=0.11) for CRT/G and CRT/C respectively. Comparing CRT and CT groups, mOS were not significantly different for LA patients, and longer for BR patients (14.4m vs. 5.5m) although this is likely due to confounding factors such as physician preference and patient selection. No significant differences were noted for grade 3/4 toxicities between both CRT groups. Conclusions: In this series, CRT/G in both BR and LA setting were associated with a high surgical resection rate with acceptable toxicity and potentially improved survival for patients not felt to be surgical candidates at presentation. These data warrant validation in larger prospective randomized studies.
Phase I study of cisplatin/carboplatin/irinotecan (CPI) regimen in patients with ED small-cell lung cancer
Authors: M. Ichiki, Y. Yoshida, A. Ishimatsu, S. Minami, K. Taguchi, K. Tachibana, H. Aizawa
Journal: Journal of Clinical Oncology (2007)

18202 Cisplatin/irinotecan(IP) is standard regimen for ED-SCLC in Japan. Cisplatin (CDDP)-based treatment requires copious hydration, which can lead to a deterioration of outpatients’ quality of life. CDDP and carboplatin (CBDCA) have a common active form, but are associated with different adverse reactions. We considered that the combined use of these two agents could increase the dose intensity of active form platinum complexes without enhancing their toxicities. The IP was modified to nearly half the dose of CDDP/CBDCA to facilitate outpatient administration. We conducted a phase I study to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of this modified regimen for patients with ED-SCLC and stage IV NSCLC. Eligibility criteria included: PS 0–1, age &lt;75 yrs, no prior therapy, measurable disease, adequate organ functions. DLT was defined as follows: 1) grade 4 neutropenia lasting 4 days or febrile neutropenia, 2) grade 4 thrombocytopenia, 3) prolongation of treatment due to toxicity, 4) grade 3 or worse non-hematological toxicity. Three patients were enrolled at level 1(CDDP/CBDCA: 25 mg/m 2 /AUC2), 3 patients at level 2 (25 mg/m 2 /AUC 2.5) and 3 patients at level 3 (30 mg/m 2 / AUC 2.5), respectively. DLT was not observed at level 1, 2, 3. At dose level 4 (30 mg/m 2 /AUC3), two of three patients experienced DLT, suggesting this level to be the MTD. The recommended dose for phase II study is CDDP 30 mg/m 2 on day 1, CBDCA AUC 2.5 on day 1 and irinotecan 60 mg/m 2 on days 1, 8, 15. A phase II study of this regimen in ED-SCLC is ongoing. No significant financial relationships to disclose.
RELATIONSHIP OF BIOMARKERS OF OXIDIZED LIPOPROTEINS TO ETHNICITY, SUBCLINICAL ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS OVER A 10.5 YEAR FOLLOW-UP IN THE DALLAS HEART STUDY
Authors: Sotirios Tsimikas, Anand Prasad, Paul Clopton, Colby Ayers, Amit Khera, James de Lemos, Joseph Witztum
Journal: Journal of the American College of Cardiology (2017)
Erythropoietin-Inducible MicroRNA-362 Contributes to Erythropoiesis Via the Suppression of Histone Deacetylase 3.
Authors: Yusuke Yoshioka, Keiichi Sugiura, Nobuyoshi Kosaka, Yusuke Yamamoto, Norio Komatsu, Hiroshi Miyazaki, Takahiro Ochiya, Takashi Kato
Journal: Blood (2010)
PERCUTANEOUS CORONARY INTERVENTION (PCI) HAS BETTER PROGNOSIS THAN CONSERVATIVE TREATMENT IN PATIENT OVER 80 YEARS DURING NON ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI)
Authors: Anwar J. Siddiqui, Peter Reinius, Filip Maskovic, Linda Melbin
Journal: Journal of the American College of Cardiology (2017)
HOLTER FINDINGS IN ORTHOTOPIC HEART TRANSPLANTATION PATIENTS: RESULTS FROM A COHORT OF THE MOST IMPORTANT HEART TRANSPLANT REFERRAL CENTER IN COLOMBIA, SOUTH AMERICA
Authors: Juan Rico Mesa, Rafael Correa, Juan Fernando Agudelo, Elsa Vasquez, Alvaro Quintero, Gloria Saenz, Ricardo Fernandez, Juan Ramirez
Journal: Journal of the American College of Cardiology (2017)
The impact of family information services on genetic testing uptake among relatives in Lynch syndrome families.
Authors: Henry T. Lynch, Sarah G. Buxbaum, Carrie L. Snyder, Mark Stacey, Trudy G. Shaw, Patrick M. Lynch
Journal: Journal of Clinical Oncology (2013)

1573 Background: A mismatch repair (MMR) pathogenic mutation in an index patient provides a basis for predictive mutation testing in at-risk members of Lynch syndrome (LS) families. Mutation carriers warrant aggressive surveillance. As importantly, non-carriers can safely follow general population screening guidelines. However, penetration of predictive testing has been disappointing in first-degree relatives (FDR), and has been even more limited in second- and more distant-degree relatives, even though the benefits can be as great as in FDRs. Family Information Services (FISs), involve an in-person session in which expert providers and counselors meet with multiple family members in a convenient geographical location. Education and counseling are intended to lead to testing for the family MMR mutation, followed by appropriate surveillance. Methods: LS families with a known MMR mutation (n=97) were targeted for this study. Selection for FIS was based on family size and convenient geographic location. Twenty-eight were offered an FIS and 69 received standard care (mailed educational material and invitation for testing). Data were collected on testing rates. Results: In at-risk patients that did receive FIS, 20.4% (std dev = 11.4%, 95% CI: 16.0 to 24.8%, range: 3 to 57.5%) were DNA tested, whereas in families that did not receive FIS, 12.9% (std dev = 10.8%, 95% CI: 10.2 to 15.5%, range: 0 to 43.5%) were DNA tested. The difference in proportions tested between the FIS and non-FIS families was statistically significant (p=0.003) and was more pronounced in family members whose relationship to the proband was beyond first-degree (p&lt;0.0001). Of those individuals that attended an FIS, 81.1% were tested. Conclusions: Genetic counseling in the FIS setting facilitates uptake of predictive mutational testing in FDRs and in more distant at-risk relatives. However, the FIS is time-consuming and labor intensive; more efficient means of disseminating LS risk information and the benefits of predictive testing in more distant relatives are needed. A cost-effectiveness analysis as well as a randomized study that controls for participation bias must be done.
INCREMENTAL PROGNOSTIC VALUE OF CORONARY CALCIUM SCORING IN PATIENTS UNDERGOING 82-RUBIDIUM MYOCARDIAL PERFUSION IMAGING
Authors: Amjad M. Ahmed, Ihab Sulaiman, Dalia Ahmed, Mousa Alfaris, Misfer Aldosari, Ahmed Aljizeeri, Ahmed Alsaileek, Abdulbaset Sulaiman, Sherif Sakr, Mouaz Al-Mallah
Journal: Journal of the American College of Cardiology (2017)
The Hyde Amendment at 40 Years and Reproductive Rights in the United States
Authors: Eli Y. Adashi, Rachel H. Occhiogrosso Abelman
Journal: JAMA (2017)

This Viewpoint discusses the evolution of the Hyde Amendment, which in 1976 prohibited use of medical funds to pay for abortion except when the mother’s life is endangered, and efforts since then to nullify the amendment or codify it as a federal statute.
LIPID TRANSFER TO HDL IN PATIENTS WITH HEART FAILURE WAS DIMINISHED AND IS CORRELATED WITH SEVERITY OF THE DISEASE
Authors: Ana Elisa Marabini Martinelli, Raul C. Maranhao, Priscila O. Carvalho, Milena N.C. Curiati, Thauany M. Tavoni, Fatima R. Freitas, Antonio Barretto
Journal: Journal of the American College of Cardiology (2017)
ClearCell FX: A microfluidic system for label-free circulating tumor cell enrichment.
Authors: Andrew Wu, Ali Asgar Bhagat, Man Chun Leong, Chwee Teck Lim
Journal: Journal of Clinical Oncology (2014)

e22023 Background: Detection and characterization of rare circulating tumor cells (CTCs) are pivotal to early cancer detection and can provide insights into tumor biology leading to better cancer management. However, due to their extremely low abundance, CTC detection and enrichment has been a technical challenge. Although, many techniques and platforms have been recently developed to address problem, they are often limited to processing low sample volumes, are highly susceptible to clotting and frequently rely on antibodies for CTC capture. Methods: CTCs from metastatic Breast and Lung Cancer patients were enriched from peripheral blood using the Spiral microfluidic biochip and the automated ClearCell FX system. Blood was collected in EDTA tubes. After initial red blood cell lysis, the nucleated cellular fraction was loaded on the fully automated system, minimizing user steps and providing robust reproducible performance required for clinical use. Centrifugal forces inherent to spiral shaped microchannels enabled continuous, size-based enrichment of CTCs. Enriched CTCs were analysed by immunofluorescent staining. Detection of relevant mutations (ALK) was performed using fluorescence in situ hybrization (FISH). Results: The ClearCell FX performance was validated using cancer cell lines, achieving >50% recovery with 4log10 leukocyte depletion. The system can process 7.5 mL blood samples in an hour and the large channels dimensions eliminate any issues arising from channel clogging. CTCs were successfully detected in all samples collected from patients with metastatic lung and breast cancer (100% detection rate; n=40). FISH assays on the enriched cells showed good concordance for NSCLC samples harbouring EML4-ALK fusion mutations. Conclusions: The ClearCell FX provides a novel method to isolate CTCs from blood in their native state. The cells remain untagged with any antibodies and hence are more viable for propagation and other downstream analysis including PCR, next-generation sequencing (NGS) and FISH. The system addresses key challenges of the next generation CTC assays including antibody independent isolation, high sensitivity and throughput, and single-step retrieval of potentially viable CTCs.
Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.
Authors: Giovenzio Genestreti, Giulio Metro, Hirotsugu Kenmotsu, Kazushige Wakuda, Monica Di Battista, Giovanna Cavallo, Enrico Franceschi, Marco Bartolotti, Federica Carloni, Alberto Bongiovanni, Marco Angelo Burgio, Claudia Casanova, Marcello Tiseo, Emanuela Scarpi, Taner Korkmaz, Selcuk Seber, Roopa Somaraj Kurup, Raffaele Califano
Journal: Journal of Clinical Oncology (2014)

7600 Background: Rechallenge might be used as rescue therapy in progressing platinum-sensitiveSmall Cell Lung Cancer (SCLC). This international multicenter retrospective analysis evaluates the clinical outcomes of SCLC patients treated with this strategy. Methods: We retrospectively collect each institutional data warehouse of platinum-sensitive SCLC treated with platinum/etoposide rechallenge. Primary endpoint was overall survival (OS) from diagnosis and from the rechallenge of chemotherapy (PPS). Secondary endpoints were response rate (RR) and Progression-Free Survival2 (PFS2) yielded by rechallenge. Results: We reviewed 2000 SCLC patients from 9 institutions. One hundred twelve (5.6%) with sensitive SCLC were treated with first-line platinum/etoposide rechallenge. There were 72 (64%) males and 40 (36%) females with a median age of 64 years (range 40–83). At diagnosis, 49 (44%) patients had limited disease (LD) whereas 63 (56%) had extensive disease (ED). ECOG Performance Score (PS) was <1 and >1 in 87% and 13% of patients, respectively. First-line chemotherapy yielded: 14 % complete response (CR), 84% partial response (PR) and 2% stable disease (SD). Mean number of cycles of rechallenging chemotherapy was 3.6 (range 1-7). Carboplatin and cisplatin were administered in 96 (86%) and 16 (14%) of the patients, respectively. There were 3% CR, 42% PR, 19% SD, 27% progressive disease and 9% not evaluable yielding a median PFS2 of 5.5 months (95% CI 4.4-6.3). Median OS and PPS were 21.4 months (95% CI 19.8-24.1) and 7.9 months (95% CI 6.9-9.7), respectively. Forty (36%) patients received further chemotherapy. At the multivariate analysis stage at diagnosis, PS and platinum (carboplatin or cisplatin) used in rechallenge were not prognostic factors, while time from diagnosis to first progression disease (PFS1) > 150 days (p<0.0001) was. Conclusions: Rechallenge may be an efficacy option in patients with platinum sensitive disease with a PFS1 > 150 days.
Airway Necrosis and Barotrauma after Ecstasy Inhalation
Authors: Evi Van den Kerckhove, Laurence Roosens, Vasiliki Siozopoulou, Walter Verbrugghe, Jelle Aerts, Jef Huyskens, Hannelore Raemen, Philippe G. Jorens
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
GATA2 Is Overexpressed in 46% of Patients with AML and Normal Karyotype. The Mutational Pattern FLT3-ITD/GATA2/WT1 Could Define a Group of Patients with Normal Karyotype and AML-M1 Subtype.
Authors: Idoya Lahortiga, Iria Vazquez, Nerea Marcotegui, Eva Bandres, Raquel Malumbres, Maria J. Larrayoz, Carmen Vicente, Jose Cervera, Jesus M. Hernandez, Jesus Garcia-Foncillas, Maria T. Ardanaz, Filomena Floristan, Maria J. Calasanz, Maria D. Odero
Journal: Blood (2005)
Some Unusual Paraneoplastic Syndromes
Authors: Ravi S. Agrawal, Jaya R. Agrawal, Bharat L. Agrawal, Amaresh R. Nath, Asha R. Agrawal, J.C. Gaddipat, Richard F. Garnett
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.09.104 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12829686 Some Unusual Paraneoplastic Syndromes CASE 3. METASTATIC PULMONARY CALCIFICATION CAUSING HYPOXEMIA IN MALE BREAST CANCER Ravi S. AgrawalxRavi S. AgrawalSearch for articles by this author , Jaya R. AgrawalxJaya R. AgrawalSearch for articles by this author , Bharat L. AgrawalxBharat L. AgrawalSearch for articles by this author , Amaresh R. NathxAmaresh R. NathSearch for articles by this author , Asha R. AgrawalxAsha R. AgrawalSearch for articles by this author , J.C. GaddipatxJ.C. GaddipatSearch for articles by this author , Richard F. Garnett JrxRichard F. Garnett JrSearch for articles by this author Show More Cancer and Blood Disease Center, and Department of Medicine, Reid Hospital & Health Care Services, Richmond, IN https://doi.org/10.1200/JCO.2003.09.104 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
ASSOCIATION OF GENETIC RISK SCORE WITH BURDEN OF ATRIAL FIBRILLATION: AN ENGAGE AF-TIMI 48 ANALYSIS
Authors: Christian T. Ruff, Dov Shiffman, James Devlin, Robert Giugliano, Elliott Antman, Marco Trevisan, Francesco Nordio, Alexander Vandell, Michele Mercuri, Marc Sabatine
Journal: Journal of the American College of Cardiology (2017)
Predictive value of tumor infiltrating lymphocytes (TIL) for response to breast cancer neoadjuvant chemotherapy (NCT).
Authors: Elena Garcia-Martinez, Gines Luengo-Gil, Asuncion Chaves, Lorena Velazquez, Enrique Gonzalez-Billalabeitia, Maria Angeles Vicente-Conesa, Teresa Garcia, Elisa Garcia-Garre, Vicente Vicente, Francisco Ayala
Journal: Journal of Clinical Oncology (2013)

585 Background: The association of tumor microenvironment immune response with outcome after breast cancer (BC) NCT has been suggested by several studies. However, the relevance of each TIL subpopulation is still controversial. The objective of this study was to evaluate the predictive and prognostic value of TIL before and after NCT in patients with BC. Methods: We analyzed TIL and CD68 cells in pre- and post-chemotherapy biopsies of BC patients treated with NCT (80.4% sequential AC-docetaxel). A tissue microarray with paired pre- and post-NCT biopsies was built, and stained with immunohistochemistry (IHC) for CD3, CD4, CD8, CD20, FOXP3 and CD68. Morphometric analysis (TIL count/mm 2 ) was performed after slide scanning and digitalization. Results: We included 121 consecutive patients with invasive BC, most of them with stages IIB (28%) or IIIA-C (56.4%). IHC phenotype: 50.4% Her2- hormone-sensitive (HS), 13.2% Her2+ HS, 10.7% Her2+ non-HS, and 21.5% triple negative. Pathologic complete response (pCR): 17.4%. Median overall survival (OS) and disease free survival (DFS) has not been reached (median follow-up: 60 months). Higher than median pre-NCT TIL infiltration was predictive of pCR to NCT: CD3 &gt; 172/mm 2 (p=0.001; Hazard Ratio [HR]: 9,61, 95% confidence interval [95%CI] 2.49–37.02); CD4 &gt; 67/mm 2 (p=0.001; HR: 8.82, 95%CI 2.43–31.96); CD20 &gt; 42/mm 2 (p=0.001; HR: 8.71, 95%CI 2.31–32.74). Logistic regression multivariate models including grade and IHC phenotype confirmed the independent predictive value of higher pre-NCT CD3, CD4, and CD20 for pCR. In the group of patients with HS Her2- BC without pCR (n=44), higher infiltration (cut-point: median value) by some TIL subpopulations and by CD68 cells in post-NCT residual tumor associated to lower DFS: CD8 &gt; 37/mm 2 (log-rank; p=0.04), CD20 &gt; 14/mm 2 (p=0.07) and CD68&gt; 39/mm 2 (p=0.06). Conclusions: Higher pre-treatment CD3, CD4 and CD20 TIL predicted pRC in patients with invasive BC receiving anthracyclines and taxanes NCT, while higher infiltration of residual tumor by CD8 associated to worse DFS in patients with HS Her2- BC without pCR after NCT. TIL might be useful as predictive factors in the setting of NCT for BC [Supported by GEICAM-Beca Ana Balil].
COMPARISON OF IN-HOSPITAL OUTCOMES OF SEPTIC SHOCK PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION: A RETROSPECTIVE PROPENSITY-MATCHED ANALYSIS
Authors: Osama Tariq Niazi, Ahmad Alkhalil, Adebayo Olusanya, Shashank Jain, Shervin Golbari, Riju Banerjee, Luke Chong, Victor Mazza, Marc Klapholz, Alfonso Waller
Journal: Journal of the American College of Cardiology (2017)